Weleader Biomedical CoROCO:7713 -1.54%47 ROA % is 9.68% as of Dec. 2025, which is 4% above its 10-year median of 9.27. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 85.4% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Weleader Biomedical Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$231 Mil.
Weleader Biomedical Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$2,386 Mil. Therefore, Weleader Biomedical Co's annualized ROA % for the quarter that ended in Dec. 2025 was 9.68%.
The historical rank and industry rank for Weleader Biomedical Co's ROA % or its related term are showing as below:
ROCO:7713'
s ROA % Range Over the Past 10 Years
Min: 5.55 Med: 9.27 Max: 12.39
Current: 9.4
During the past 6 years, Weleader Biomedical Co's highest ROA % was 12.39%. The lowest was 5.55%. And the median was 9.27%.
ROCO:7713's ROA % is ranked better than 85.4% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs ROCO:7713: 9.40
Weleader Biomedical Co (ROCO:7713) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Weleader Biomedical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's ROA % distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Weleader Biomedical Co (ROCO:7713) has a ROA % of 9.68% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Weleader Biomedical Co and its competitors. This is near median its historical median of 9.27. Over the past decade, Weleader Biomedical Co's ROA % has ranged from 5.55 to 12.39. According to the industry distribution chart, Weleader Biomedical Co ranks #125 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 14.6%.
Is Weleader Biomedical Co's ROA % too high?
Weleader Biomedical Co's current ROA % of 9.68% is near median its 10-year median of 9.27. Over the past 10 years, this metric has ranged from a low of 5.55 to a high of 12.39. The Medical Devices & Instruments industry median ROA % is 0.55. Weleader Biomedical Co's value of 9.68% is 1676.1% above this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #125 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #125 out of 856 companies for ROA %. This places Weleader Biomedical Co in the top 15% of its industry — outperforming the majority of peers. The industry median ROA % is 0.55. Weleader Biomedical Co's value of 9.68% is 1676.1% above this benchmark. Historically, Weleader Biomedical Co's own ROA % has ranged from 5.55 to 12.39 over the past decade. While the company's 10-year median is 9.27 vs. the industry median of 0.55, Weleader Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current ROA % of 9.68% is 1676.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current ROA % is 9.68%, which is near median its own 10-year median of 9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current ROA % of 9.68%. The current ROA % is 9.68%, which is near median its 10-year median of 9.27 and 1676.1% above the Medical Devices & Instruments industry median of 0.55. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current ROA % is 9.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score
Get the complete analysis for ROCO:7713
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
